# A Study of Relatlimab Plus Nivolumab in Combination With Chemotherapy vs. Nivolumab in Combination With Chemotherapy as First Line Treatment for Participants With Stage IV or Recurrent Non-small Cell Lung Cancer (NSCLC)

> **NCT04623775** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Bristol-Myers Squibb** · enrollment: 468 (actual)

## Conditions studied

- Non-small Cell Lung Cancer
- Recurrent Non-small Cell Lung Cancer
- Metastatic Non-small Cell Lung Cancer

## Interventions

- **BIOLOGICAL:** Nivolumab
- **BIOLOGICAL:** Relatlimab
- **DRUG:** Carboplatin
- **DRUG:** Cisplatin
- **DRUG:** Paclitaxel
- **DRUG:** Nab-Paclitaxel
- **DRUG:** Pemetrexed

## Key facts

- **NCT ID:** NCT04623775
- **Lead sponsor:** Bristol-Myers Squibb
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2021-02-17
- **Primary completion:** 2024-01-11
- **Final completion:** 2026-02-27
- **Target enrollment:** 468 (ACTUAL)
- **Last updated:** 2025-10-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04623775

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04623775, "A Study of Relatlimab Plus Nivolumab in Combination With Chemotherapy vs. Nivolumab in Combination With Chemotherapy as First Line Treatment for Participants With Stage IV or Recurrent Non-small Cell Lung Cancer (NSCLC)". Retrieved via AI Analytics 2026-07-19 from https://api.ai-analytics.org/clinical/NCT04623775. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*